Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7-H3CART in Recurrent Glioblastoma Multiforme
NCT05474378Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Jul 2022
- Primary completion
- Feb 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of B7H3-CART in glioblastoma multiforme (GBM) (2 arms), sponsored by Stanford University. Primary endpoints: Number of successful manufacturing product that met minimum assigned dose level range at 5 years and Maximum Tolerated Dose (MTD) or Recommended phase 2 dose (RP2D) at 5 years. Started Jul 2022; status: recruiting.
02
Drugs
B7H3-CART
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05474378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05474378.